Diabetes

 

STEP 1 and STEP 3 Results with Thomas Wadden, PhD

March 02, 2021

Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.

When Men Exercise Could Influence Risk of Cardiovascular Disease, Study Finds

February 23, 2021

An analysis of more than 2k patients from within the Look AHEAD study suggests the timing of physical activity could play a role in mitigating cardiovascular risk among men with type 2 diabetes considered overweight or obese.